Primary hyperoxaluria type 1 (PH1) Infusion Therapy
Primary Hyperoxaluria Type 1 (PH1) is a rare, life-threatening genetic metabolic disorder caused by a deficiency of the liver enzyme alanine-glyoxylate aminotransferase (AGT). Without this functional enzyme, the liver overproduces oxalate, a toxic metabolic byproduct that cannot be broken down by the body and accumulates in the kidneys and urinary tract.
Excess oxalate leads to recurrent calcium oxalate kidney stones, nephrocalcinosis, and progressive chronic kidney disease. Over time, systemic oxalosis can occur, where oxalate deposits cause severe damage to the heart, bones, blood vessels, and nervous system. Early diagnosis and aggressive therapy are essential to protect kidney function.
At Violet Health, we administer FDA-approved targeted therapies such as OXLUMO® (lumasiran), an advanced RNA interference (RNAi) therapy designed to reduce hepatic oxalate production at its root cause. Our medical team provides personalized infusion care, comprehensive clinical monitoring, and collaborative support alongside your nephrologist and metabolic disease specialists.
Meet our Infusion Specialists
Jalal Thwainey M.D.
Medical Director
Emilie Wojcik, N.P.
Director of Clinical Services
For Provider
Simplify patient referrals and offer advanced treatment options with our infusion partnership program.
For Patient
There may be a better way to manage your condition – explore infusion therapy.